Introduction
Sepsis is a common, deadly, and expensive disease worldwide. Although sepsis has long been recognized, it was not clinically de ned until the late th century, mainly because the lack of e ective antimicrobials and supportive care prevented patients with sepsis from surviving long enough to be studied or to develop sequelae of organ dysfunction. As care and outcomes improved, the need for more precise terminology became evident both for clinicians and for researchers designing clinical trials. In the early s, a consensus statement was developed by the American College of Chest Physicians and the Society of Critical Care Medicine (SCCM) that de ned systemic in ammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock in terms of both clinical and laboratory abnormalities ( g ), emphasizing a continuum of acute in ammation and organ dysfunction. Revised modestly in , these de nitions have formed the basis of the past quarter century of research into sepsis and catalyzed the evolution of its clinical recognition and management, and the design of clinical trials. However, the sensitivity and speci city of SIRS criteria have been questioned, as has the contention that SIRS, sepsis, severe sepsis, and septic shock occur along a continuum rather than as discrete clinical entities. In February , the European Society of Intensive Care Medicine and the SCCM published new consensus de nitions of sepsis and related clinical criteria ( g ; Sepsis-). The most important changes were:
• The terms SIRS and severe sepsis were eliminated • Sepsis is now de ned as life threatening organ dysfunction caused by a dysregulated host response to infection
• Organ dysfunction is newly de ned in terms of a change in baseline SOFA (sequential organ failure assessment) score
• Septic shock is de ned as the subset of sepsis in which underlying circulatory and cellular or metabolic abnormalities are profound enough to increase mortality substantially. Novel mechanistic insights about sepsis have not yet translated into speci c drug treatments. However, mortality has declined even as the severity and incidence of sepsis have risen. In this review, which is aimed at specialists in critical care and related areas, we critically review the past years of published studies on the epidemiology, risk factors, microbiology, pathogenesis, and treatment of sepsis. 
STAT E O F T H E A RT R E V I E W

HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE
A year old survivor of severe pneumococcal sepsis and acute respiratory distress syndrome who required a lung transplant, as well as his mother, kindly accepted an invitation to review the manuscript as patient reviewers for The BMJ . They were asked to indicate which sections or information were of greatest importance and relevance to them and which sections were the least useful. Alternatively, or in addition, they could write general comments about what they thought was missing or underemphasized. As a result of their input, we clarified several areas of the article and put more emphasis on the role of vaccines in preventing illness and on improvements in supportive critical care.
A B ST RAC T
Sepsis, severe sepsis, and septic shock represent increasingly severe systemic inflammatory responses to infection. Sepsis is common in the aging population, and it disproportionately a ects patients with cancer and underlying immunosuppression.
In its most severe form, sepsis causes multiple organ dysfunction that can produce a state of chronic critical illness characterized by severe immune dysfunction and catabolism. Much has been learnt about the pathogenesis of sepsis at the molecular, cell, and intact organ level. Despite uncertainties in hemodynamic management and several treatments that have failed in clinical trials, investigational therapies increasingly target sepsis induced organ and immune dysfunction. Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of e ective antibiotics, and other improvements in supportive care for critically ill patients. These improvements include lung protective ventilation, more judicious use of blood products, and strategies to reduce nosocomial infections.
persisted across di erent severities of illness, geographic regions, and hospital types and sizes. Cumulatively, the highest quality epidemiologic studies indicate that severe sepsis is becoming both more common and less deadly.
Host differences in the incidence and outcome of sepsis Demographics
Women have a lower incidence of severe sepsis, yet mortality results are mixed. - The causes of this sex di erence remain unexplained but may involve the e ect of sex hormones on innate and adaptive immunity and on the cardiovascular response to cytokine signaling. Race seems to be another important risk factor for sepsis. The incidence of sepsis in the US is higher in non-whites (relative risk . ), especially African-Americans. Similar results were reported in a subset of US states, and in a separate detailed analysis from New Jersey. Possible explanations for these di erences include disparities in access to timely healthcare, immunizations, poverty, and comorbidities including HIV, diabetes, chronic kidney disease, and substance use disorders.
-However, the increased incidence of infection and organ dysfunction in patients of African descent seems to persist a er controlling for many of these factors, suggesting that genetic factors may also be involved.
Older patients are far more likely to develop sepsis. A study of discharge data from US hospitals reported that patients years and older comprised % of the population but nearly % of sepsis cases (relative risk . ). Older patients were twice as likely to have comorbid conditions, but a multivariate analysis that adjusted for these conditions in addition to race, sex, source of infection, and severity of illness found that patients with sepsis who were aged or more were . times more likely to die. Furthermore, patients who survived were less likely to be discharged home. A more recent study
Sources and selection criteria
We identi ed references for this review through searches of publications listed by PubMed from to February . We used the search terms "sepsis", "septic", "SIRS", "infection", "epidemiology", "pathophysiology", "microbiology", "resuscitation", "history", "treatment", "therapy", "cancer", "malignancy", "age", "ethnicity", "race", "immunosuppression", "genetic", "endothelial", "epithelial", "coagulopathy", "cytokine", "guidelines", and "resolution". References were also identi ed from relevant review articles. We looked at in vitro, animal, and human studies, including meta-analyses. Only articles published in English were reviewed. We screened more than articles of evidence classes I-IV and included classes I-III. We excluded articles published in non-peer reviewed journals, case reports, and small uncontrolled series. The nal reference list was based on relevance to the topics covered in the review.
Epidemiology
Over the past years the incidence of severe sepsis has substantially increased, partly because of the increasing age of the population. The latest estimates in the United States, Europe, and the United Kingdom range between . / and / of the population.
-Remarkably, in-hospital mortality for patients with sepsis during this period has decreased from % to %. A recent study that used a database of prospectively collected data from more than % of all intensive care unit (ICU) admissions in Australia and New Zealand between and con rmed these trends in both incidence and mortality. Using objective de nitions of acute organ dysfunction, severe sepsis in patients admitted to the ICU was estimated to increase from . % to . % during the study period. At the same time, hospital mortality in severe sepsis declined from % to %, an improvement that
Fig | Previous and recently revised definitions of sepsis and related syndromes. *As assessed by an acute change of ≥ points in the sequential organ failure assessment score (components: partial pressure of oxygen in arterial blood/fractional inspired oxygen (PaO /FIO ) ratio, Glasgow coma scale, mean arterial pressure, vasopressor use, serum creatinine or urine output, bilirubin, and platelet count). We used the previous definitions in this review because they are central to the understanding of the past quarter century of research into the epidemiology, pathogenesis, and treatment of sepsis, including all ongoing clinical trials reported a remarkable increase in the risk of death by infection before the age of if a biological parent died of an infectious cause (relative risk . ( % con dence interval . to . ) v . ( . to . ) for an adoptive parent). Although generated in an era before the widespread use of antibiotics, these data provide strong evidence that the tendency to succumb to overwhelming infection is in part heritable. A limited number of patients have congenital immunode ciencies related to defects in innate and adaptive immune processes, including pattern recognition receptors, complement, cytokines, and e ector cells. Despite an extensive search for more common and subtle genetic variants that predispose to sepsis, only a few candidates have been found. Genome-wide association studies in patients with sepsis have been difcult given challenges in the de nition of sepsis and the consequent heterogeneity of these patients.
Polymorphisms in Toll-like receptor (TLR ) and TLR have been associated with increased susceptibility to Gram negative septic shock, candidemia, and invasive aspergillosis. Interestingly, the Asp Gly TLR polymorphism may confer protection against cerebral malaria. This could explain its increased frequency in people from sub-Saharan Africa, and it might be related to ethnic di erences in the incidence and severity of sepsis. NOD (nucleotide binding oligomerization domain containing protein ) and the Asp Gly variants were additive in increasing the risk of bacteremia and hospital mortality in a study of nearly Belgian ICU patients. A genome-wide association study of patients with septic shock of European ancestry from ICUs from North America and Australia identi ed only one single nucleotide polymorphism that was associated with increased day mortality and organ dysfunction. This was the C allele of SVEP ( % allele frequency in European populations), which encodes a cell adhesion molecule with multiple domains capable of interacting with complement, growth factors, integrins, and cytokines. Finally, in a recent genome-wide association study involving four cohorts of patients admitted to European ICUs with sepsis, severe sepsis, and septic shock from pneumonia or intra-abdominal infection, a common ( %) variant of the FER gene (Fps/FES related tyrosine kinase, a cytosolic protein thought to be involved in leukocyte recruitment) was associated with increased survival, although only in patients with pneumonia.
Modifiable risk factors
Alcohol consumption has been shown in adjusted epidemiologic analyses to increase the risk of sepsis and related organ failure and mortality.
Although tobacco is now a well established risk factor for acute respiratory distress syndrome (ARDS), evidence linking smoking to sepsis has been less robust. In a study of outpatients observed for a ve year period during which cases of sepsis were detected, tobacco use was signicantly associated with incident sepsis (hazard ratio . ). Cigarette smoking has been associated with a several-fold increase in the risk of invasive pneumococcal disease, and it has been shown to increase the risk of septic shock (odds ratio . ) and day mortality ( . ) in pneumopublished in focused on longer term mortality in patients years or more treated for severe sepsis in the US Veterans A airs healthcare system in the mids. Of the % of patients who survived for at least days a er the initial episode, an additional % had died by one year and % by two years, with the highest mortality associated with comorbid cirrhosis or metastatic cancer. Thus, advancing age is a strong risk factor for the incidence of sepsis and mortality from sepsis, and this is explained in part by the presence of comorbid conditions. Accordingly, the aging of the population probably explains much of the rising incidence of sepsis in industrialized societies.
Immunosuppression and cancer
Conditions that suppress innate and adaptive immunity are risk factors for sepsis. A multicenter study of sepsis in French ICUs estimated that immunosuppression was associated with an increased incidence of severe sepsis (odds ratio . ). Chronic conditions that suppress the immune system-including HIV/AIDS, cirrhosis, asplenia, and autoimmune disease-are heavily represented in large epidemiologic studies of patients with sepsis.
An observational study published in of patients admitted to
French ICUs between and with severe sepsis or septic shock found that % were immunocompromised from AIDS, solid organ transplantation, neutropenia, solid or hematologic cancer without neutropenia, in ammatory disorder, and primary immunode ciency. Only AIDS, neutropenia, and cancer were independent risk factors for day mortality compared with immunocompetent patients.
Patients with cancer are o en immunosuppressed, from both the cancer and its treatment. An analysis of ICD-(international classi cation of diseases, th revision) codes from six US states found that patients with cancer had a relative risk for severe sepsis of nearly ( . cases/ cancer population), along with % higher hospital mortality ( % v %), and a three times longer hospital stay compared with patients without cancer. Patients with lung and hematologic cancers fared the worst. An analysis of patients with cancer admitted with sepsis to a single Brazilian ICU between and reported % mortality at six months in patients with severe sepsis. The best predictors of mortality included low performance status (odds ratio . ), recurrence or progression of cancer ( . ), infectious source other than urine ( . ), and respiratory ( . ) or renal ( . ) impairment. Similarly, a retrospective analysis of patients with cancer admitted with septic shock to French ICUs between and identi ed mechanical ventilation ( . ), renal replacement therapy ( . ), and fungal infection ( . ) as independent risk factors for mortality. This study also reported a steep decline in ICU mortality in patients with cancer and septic shock from % in to % in , and made the important observation that outcomes were better in high volume centers.
Genetic variants
A landmark study of more than people who had been adopted in the s to the s in Denmark followed by the abdomen ( %), bloodstream ( %), and renal or genitourinary tract ( %). Of the % of infected patients with positive microbiology, % of isolates were Gram positive ( Staphylococcus aureus alone accounted for %), % Gram negative ( % Pseudomonas spp and % Escherichia coli ), and % fungal. Prevalence data are notably limited by the ability to grow and identify organisms using standard microbiologic techniques. For example, Streptococcus pneumoniae is thought to be the most common cause of bacterial pneumonia worldwide, yet it is not o en identi ed in clinical specimens. Interestingly, major regional di erences in the prevalence of certain drug resistant organisms were described ( g ), including methicillin resistant S aureus (MRSA) and strains of Klebsiella , Pseudomonas , and Acinetobacter .
Several groups have studied the EPIC II data to generate important additional insights into the microbiology of sepsis. Of the patients, had candida bloodstream infections, and these patients had much higher ICU mortality ( % v -%) and length of hospital stay than patients with bacteremia. MRSA infections have been independently associated with a hospital mortality nearly % higher than methicillin sensitive S aureus ones. However, a separate analysis reported that a er adjusting for covariates, patients admitted to ICUs in countries with a high prevalence of MRSA and other drug resistant pathogens did not fare worse than those admitted to ICUs in countries with less resistant pathogens. Of the % of patients with sepsis and an abdominal infectious source, % had undergone emergency surgery, and % had positive microbiology, most o en Gram negative bacteria coccal pneumonia.
Smoking also seems to predispose patients to postoperative infections.
A meta-analysis in also found that vitamin D de ciency increases the risk of sepsis (relative risk . ), although whether supplementation mitigates this risk remains unclear. Finally, vaccination has been shown to reduce the incidence of sepsis caused by speci c pathogens, including Haemophilus in uenzae .
Causes
Non-infectious
The term SIRS captures those patients who develop a clinical picture of sepsis without an identi able infection ( g ). Many of these patients subsequently develop evidence of infection, but several sterile in ammatory conditions can also progress to shock and multiorgan failure. These include pancreatitis, tissue ischemia, trauma and surgical tissue injury, burns, thromboembolism, vasculitis, drug reactions (including neuroleptic malignant syndrome), and autoimmune and neoplastic processes such as lymphoma and hemophagocytic lymphohistiocytosis.
Infectious
The Extended Prevalence of Infection in Intensive Care (EPIC II) study gathered extensive demographic, physiological, bacteriological, therapeutic, and outcome data from more than adult patients in ICUs from countries on a single day in May , and it provides the best recent evidence on the infectious causes of sepsis. Of the patients classi ed as infected, the site of infection was most commonly the lungs ( %), Widespread tissue factor expression, fibrin deposition, and impaired anticoagulant mechanisms (including activated protein C) can produce disseminated intravascular coagulation (DIC), a syndrome associated with increased organ dysfunction, bleeding (owing to consumption of platelets and clotting factors), and mortality.
The endothelial changes in severe sepsis are associated with altered barrier function in other organs ( g ). More permeable lung capillaries result in the accumulation of protein-rich edema uid in the interstitial spaces of the lung, and in the presence of sepsis induced alveolar epithelial barrier dysfunction, the interstitial edema uid oods into the alveoli. These changes result in perfusionventilation mismatch, arterial hypoxemia, and reduced lung compliance: ARDS.
Combined breakdown of both the endothelial and epithelial barriers extends beyond the lung and is a key mechanism in widespread lethal organ dysfunction. The gut epithelium becomes more permeable in the setting of hypercytokinemia. This increased permeability sets in motion a vicious cycle of bacterial translocation, gut injury by luminal contents including activated pancreatic enzymes (autodigestion), and worsening systemic in ammation that can perpetuate multiple organ dysfunction. Indeed, in a prospective observational study of critically ill patients in Canada, intestinal permeability independently predicted subsequent multiple organ dysfunction. In the liver, sepsis impairs hepatocyte clearance of bilirubin (causing cholestasis) and many other crucial hepatic functions, including the transport and processing of enteric pathogen lipids, further stimulating systemic in ammation.
Acute kidney injury (AKI) is common in severe sepsis and substantially increases the risk of death. Although in the past septic AKI has been attributed to reduced renal perfusion and widespread tubular necrosis, little evidence supports the notion that either of these mechanisms are common or severe enough in sepsis to explain the profound degree of renal impairment.
Rather, septic AKI seems to involve more complex and subtle mechanisms of cytokine and immune mediated microvascular and tubular dysfunction.
The nervous system is not simply an injured bystander in severe sepsis but an active participant in its early development, playing mostly an anti-inflammatory role. Carotid body chemoreceptors, vagal a erents, and brain areas with a constitutively permeable blood barrier respond to local and systemic cytokines, signaling to brainstem nuclei, which in turn send vagal, cholinergic e erents that inhibit in ammatory cytokine production by innate immune cells in the spleen, gut, and elsewhere. Indeed, vagal nerve stimulation has been shown to attenuate cytokine signaling and endothelial injury in animal models of sepsis as well as shock from ischemia-reperfusion, burns, and pancreatitis.
Encephalopathy is an early and common clinical nding in severe sepsis that can range from mildly impaired concentration to deep coma. Delirium, as assessed by the confusion assessment method (CAM)-ICU method, ( %). ICU mortality was highest for abdominal sepsis ( %), and independent mortality predictors included hematologic cancer, cirrhosis, mechanical ventilation, and renal replacement therapy. Finally, a study of the patients in EPIC II who had cirrhosis found a higher prevalence of infection (of which a greater proportion were abdominal), a higher frequency of MRSA infections, and a much higher hospital mortality rate ( % v % overall; % v % for septic shock).
A point prevalence study of pediatric sepsis (SPROUT), similar to EPIC II, which focused on sites in countries, was published in . Of the children with severe sepsis ( . % prevalence in the pediatric intensive care unit population), the most common primary site of infection was the lungs ( %), followed by the bloodstream ( %), abdomen ( %), central nervous system ( %), and genitourinary system ( %). The most severe cases of sepsis had positive microbiology, including % Gram negative bacteria, % Gram positive bacteria, % fungi ( % candida), and % viruses. Nearly % required mechanical ventilation, and % were receiving corticosteroids. Hospital mortality was %, higher than previous estimates, and thus more in line with recent studies in adults.
Pathogenesis
Much is now known about how sepsis causes organ injury at a molecular, cellular, and organ level.
Organ and tissue level
As sepsis progresses from a localized infection to mild systemic in ammation and on to septic shock, the cardiovascular system undergoes major perturbations that are well known to intensive care practitioners. With the widespread use of pulmonary arterial catheters in the s, it became clear that a er intravascular volume is restored, most patients with sepsis have a normal or raised cardiac output with low systemic vascular resistance. The preservation or enhancement in cardiac output occurs despite acute biventricular dysfunction that can last longer than a week.
Increased lactate in these patients predicts mortality. This has traditionally been thought to re ect tissue hypoxia as a result of hypoperfusion, a theory that stimulated much of the therapeutic focus during the past three decades on increasing systemic oxygen delivery in the setting of high-normal cardiac output.
Of note, alternative theories of sepsis induced hyperlactemia, such as aerobic glycolysis driven by enhanced adrenergic tone, have also been advanced.
The endothelium can be thought of as an organ that covers an area of nearly m and has important roles in regulating vasomotor tone, the movement of cells and nutrients into and out of tissues, the coagulation system, and the balance of in ammatory and antiin ammatory signaling. In sepsis, profound alterations to the endothelium occur, including increased leukocyte adhesion, a shi to a procoagulant state, vasodilation, and loss of barrier function, which all lead to widespread tissue edema.
Microcirculatory alterations include an impaired response to local stimulation, as well as obstruction of
"chronic critical illness" ). It has led to the increased emphasis on meticulous, evidenced based supportive critical care, which has probably helped improve outcomes in sepsis.
Cellular and molecular level
The molecular cascades unleashed by severe infection are complex, temporally dynamic, and at least partially dependent on the particular virulence factors of the invading pathogen. A thorough description of infectious agents and in ammatory and cytokine signaling is beyond the scope of this review, and the reader is referred to more thorough reviews as indicated.
Here we summarize some key pathways and themes. One study synthesized and infused recombinant tumor necrosis factor α (TNF-α, a polypeptide originally named cachectin) into rats. Within three hours the animals developed tachypnea, lactic acidosis, and lethal shock, and they were found to have areas of ischemia and hemorrhage of the lungs, gut, kidneys, pancreas, and adrenal glands. These e ects closely resembled the known sequelae of high dose endotoxin administration, thus showing that a single in ammatory macrophage derived cytokine can produce a clinical picture of septic shock. The same research group reported that infusing TNF-α blocking antibody fragments two hours before intravenous injection of E coli in anesthetized baboons prevented shock and organ failure. Importantly, this therapeutic e ect was lost if the antibody was infused any later than two hours before the bacteria, probably because of the rapid peak and decline of TNF-α signaling. This nding demonstrated the rapidly shiing cytokine milieu in serious infection, and it partly explains the failure of anti-TNF-α agents in the treatment of a heterogeneous population of patients with sepsis in the ICU.
Inflammatory signaling
The innate immune system, composed mainly of macrophages, monocytes, granulocytes, natural killer cells, and dendritic cells, has evolved to detect pathogen associated molecular patterns (PAMPs; including components of bacterial, fungal, and viral pathogens such as endotoxin and β-glucan) and damage associated molecular patterns (DAMPS; endogenous molecules released from damaged host cells, including ATP, mitochondrial DNA, and high mobility group box or HMGB ). DAMPs and PAMPs activate innate immune and some epithelial cells through pattern recognition receptors on the cell surface (toll-like receptors and C-type lectin receptors) or in the cytosol (NOD-like receptors, RIG-I-like receptors), initiating transcription of type I interferons and proin ammatory cytokines such as TNF-α, interleukin (IL)-, and IL-.
Some of these pattern recognition receptors (mostly NOD-like receptors) can assemble into molecular complexes termed in ammasomes, which are important in the maturation and secretion of the very potent cytokines IL-β and IL-, and can trigger highly in ammatory programmed cell death by caspase mediated rapid rupture of the plasma membrane, termed pyroptosis. Proin ammatory cytokines in turn: is very common in ventilated patients, and it is independently associated with mortality and long lasting neurocognitive de cits.
Infection can cause encephalopathy as a direct result of central nervous system infection, but more o en it sets in motion a series of sterile events that perturb neurologic function. Systemic endothelial dysfunction compromises the blood-brain barrier, allowing in ammatory cytokines and cells to enter the brain, causing perivascular edema, oxidative stress, leukoencephalopathy, and widespread neurotransmitter alterations.
Coincident hepatic and renal dysfunction exacerbate toxin in ux into the CNS. In addition, coagulopathy and impaired autoregulation of cerebral blood ow can together produce areas of ischemia and hemorrhage. In a series of patients with septic shock, ischemia and hemorrhage were detected at autopsy in and six patients, respectively. Finally, the early proinflammatory state in severe sepsis o en develops into a later and prolonged state of immune system dysfunction. Spleens harvested from ICU patients who had active sepsis when they died are largely depleted of CD + and CD + T cells, and the remaining splenocytes show marked reductions in stimulated cytokine production. The loss of CD + T cells seems to be mainly the result of apoptosis, and it severely impedes the ability of these patients to mount an appropriate immune response to superimposed infections. Indeed, multiple viruses (including cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and human herpesvirus ) are o en reactivated during the course of the illness, and cytomegalovirus viremia is predictive of fungal infection and day mortality. Similarly, lymphopenia four days a er the diagnosis of sepsis is associated with secondary bacterial infection and predicts mortality at days and one year. Thus, it is not surprising that in prolonged sepsis there is a microbiologic trend towards subsequent infection with less virulent organisms.
Septic organ dysfunction o en perpetuates critical illness in a self reinforcing manner through several well de ned pathways:
• ARDS o en requires mechanical ventilation, which itself can further injure the lungs and enhance systemic in ammation
• Sedatives needed to compel compliance with positive pressure ventilation can worsen septic associated encephalopathy and delirium, leading to reduced mobility, worsened catabolism, and severe neuromuscular weakness
• Intestinal barrier dysfunction causes ongoing systemic translocation of pathogenic organisms and impaired nutritional status
• Immune system dysfunction leaves the host-who is commonly being treated with broad spectrum antibiotics and has portals for nosocomial infections (endotracheal tube, intravascular, bladder catheters)-highly susceptible to new infections with resistant bacteria and opportunistic organisms.
The combined e ect of these self reinforcing processes ( g ) explains much of the morbidity of severe sepsis (including the tendency to develop what has been termed • Complement activation (especially C a) further increases generation of ROS, granulocyte enzyme release, endothelial permeability, and tissue factor expression and may cause the death of adrenal medullary cells
• Widespread immunothrombosis can result in DIC, with resultant impaired microvascular function and organ injury, along with further activation of in ammatory pathways Thus at the molecular ( g ) and tissue levels, sepsis is characterized by self reinforcing pathophysiologic processes.
Metabolic dysfunction
Even in the most severe, lethal septic shock and multiorgan failure, autopsy series show relatively little cell death outside of lymph tissues. Mitochondrial proteins and DNA are damaged by high levels of ROS, and patients with sepsis have damaged and dysfunctional mitochondria.
Potentially exacerbated by the toxic e ects of antibiotics on mitochondria, ATP levels drop, and to prevent a lethal drop in ATP cells may enter a state similar to hibernation. A generalized reduction in energy expenditure at the cellular level is consistent with retained tissue oxygen tension in sepsis, and this reduction probably exacerbates organ dysfunction as many viable cells reduce their performance of specialized functions. This leads to or exacerbates acute kidney injury, myocardial depression, hepatic dysfunction, encephalopathy, acute lung injury with increased lung endothelial and epithelial permeability to protein, and decreased barrier and transport functions of the gastrointestinal tract.
Catabolism is another increasingly recognized characteristic of severe sepsis. A prospective study of critically ill patients in England documented rapid and substantial loss of muscle mass, especially in patients with multiorgan failure. Pain, corticosteroids, immobility, and in ammatory cytokines all contribute to the rapid breakdown of muscle tissue, liberating amino acids for gluconeogenesis to fuel the glucose dependent proliferation of innate immune cells. Of note, the insulin insensitivity and hyperglycemia characteristic of sepsis and critical illness are proportional to the severity of the insult and may have evolved to ensure that glucose levels in the interstitial space (about % lower than in the blood) are adequate to support the massive immune response.
Resolution pathways
Compensatory anti-inflammatory cytokine pathways are activated even in the first hours of severe sepsis. IL-, produced by a variety of leukocytes, suppresses the production of IL-and interferon-γ, and stimulates the production of soluble TNF receptor and IL-receptor antagonist, helping to neutralize potent TNF-α and ILsignaling. At the subcellular level, autophagy provides a way to eliminate DAMPs and PAMPs by packaging pathogens and damaged organelles and proteins in vesicles targeted for lysosomal degradation, reducing in ammasome activation.
• • Upregulate tissue factor expression by blood monocytes. In combination with the release of NETS and microparticles mentioned above, intravascular tissue factor expression results in "immunothrombosis," whereby microbes are trapped within thrombi that in turn attract and further activate leukocytes.
Early damage pathways
The in ammatory cytokine response is a highly evolutionarily conserved system that achieves rapid control of minor and localized infections. However, when the response exceeds a certain threshold systemic injury occurs:
• Reactive oxygen species (ROS) such as the hydroxyl radical and nitric oxide can damage cellular proteins, lipids, and DNA, and impair mitochondrial function
Fig | The self reinforcing pathophysiologic processes involved in sepsis. Endothelial injury results in activation of monocytes and granulocytes, endothelial barrier breakdown, immunothrombosis, and disseminated intravascular coagulation. DAMPs= damage associated molecular patterns; IL= interleukin; TLR = Toll-like receptor ; TNF-α=tumor necrosis factor α A meta-analysis in of studies failed to show increased mortality in patients receiving antibiotics more than one hour (odds ratio . , . to . ) or three hours ( . , . to . ) a er the recognition of severe sepsis or septic shock. However, this study has been criticized for excluding many eligible trials, thereby increasing the chances of signal dilution and bias. The most recent guidelines from the Surviving Sepsis Campaign (SSC) recommend administration of e ective intravenous antibiotics within an hour of recognizing severe sepsis or septic shock. Although the precise temporal bene ts of antibiotics may be controversial (and unknowable given that a randomized trial would be unethical), there is consensus that e ective antibiotics should be given as soon as possible. To meet this goal, hospitals have implemented a variety of screening procedures and protocols to help identify patients with severe sepsis early, rapidly obtain microbiologic samples, and administer broad spectrum antibiotics.
Resuscitation
Although early prospective randomized trials suggested that boosting oxygen delivery improved outcomes, there were methodological problems. One prospective study of nine patients with sepsis and nine without in whom care was being withdrawn suggested that the oxygen delivery threshold for anaerobic metabolism was similar in patients with and without sepsis ( . (standard deviation . ) v . ( . ) mL/min/kg; P> . ) and that it was much lower than suspected. In the mids, two important trials in heterogeneous populations of critically ill patients targeted either a high mixed venous oxygen saturation or a supranormal cardiac output, nding that so called goal oriented therapy either did not a ect survival or signi cantly reduced it ( g ).
As enthusiasm waned for increasing oxygen delivery to patients with sepsis, an in uential single center study was published in ( g ) that randomized a more homogeneous group of patients with SIRS and hypotension (or lactate of at least mmol/L) within one to two hours of admission to the emergency department to one of two protocols for six hours. Standard therapy targeted central venous pressure of -mm Hg, mean arterial pressure of -mm Hg, and urine output of . mL/ kg/h using crystalloid or colloid infusions and vasopressors. "Early goal directed therapy" (EGDT) targeted the same three parameters as well as a central venous oxygen saturation of % using red blood cell transfusions and inotropes as needed. The EGDT group had a % absolute improvement in in-hospital mortality ( % v %; relative risk . , . to . ). On the basis of this trial, the EGDT protocol was widely adopted (including a grade C recommendation from the SSC ) and many centers began using specialized catheters to monitor central venous oxygen saturation continuously.
Although outcomes improved with so called sepsis bundles, controversy persisted over whether the resource intensive EGDT protocol was itself e ective or instead helped create the systems to recognize sepsis earlier and improve other aspects of care, such as the speed of antibiotic administration. In the past two years, three It has increasingly been recognized that resolution of in ammation a er severe infection is not simply a passive process of the fading of in ammatory pathways, but instead involves a coordinated set of cell processes and newly recognized molecular signals. Once the pathogenic organisms have been eliminated from the host, damaged cells and in ltrating leukocytes must be cleared from the tissue. If the signaling milieu is favorable, these cells undergo apoptosis and are engulfed (mostly by macrophages), a process termed e erocytosis, triggering the release of the anti-in ammatory cytokines ILand transforming growth factor β. Recently discovered families of bioactive lipids termed lipoxins, resolvins, protectins, and maresins (also released during e erocytosis) have been shown to reduce ROS, endothelial permeability, and leukocyte recruitment, and further enhance macrophage e erocytosis. Regulatory T cells (Tregs) and myeloid derived suppressor cells may also play important roles in the clearance of cytotoxic cells and production of anti-in ammatory cytokines.
Treatment
The consistent improvements in survival a er sepsis might suggest that a variety of proven, e ective treatments had been implemented. However, there are still no approved speci c molecular therapies for sepsis. Furthermore, controversy continues to surround nearly every variable in the management of sepsis, with consensus around only a few key points. Broadly speaking, attempts to normalize or enhance various aspects of the physiology of patients with sepsis (gas exchange, glucose control, oxygen delivery) have been either ine ective or harmful, emphasizing the value of large randomized trials to test what initially appear to be intuitively pleasing concepts in critically ill patients.
Early and effective antimicrobial treatment
In light of current practice, it is remarkable that as recently as the s patients presenting to the emergency department with suspected bacterial meningitis had a median three hour delay in antibiotic administration, with % of the delay occurring a er the initial encounter with the physician. This delay was commonly caused by waiting for the lumbar puncture results, even when grossly cloudy cerebrospinal uid was obtained; in community hospitals the delay was o en lengthened by the practice of deferring to the admitting internist to order antibiotics a er the patient arrived on the hospital ward.
A retrospective review of Canadian patients admitted with septic shock between and found that only % received e ective antibiotics within six hours of the onset of hypotension. Each hour of delay in antibiotic administration a er the onset of shock was associated with a nearly % reduction in survival (odds ratio . per hour delay, .
to . ). A more recent retrospective analysis in of patients admitted to ICUs with septic shock or severe sepsis also found that adjusted hospital mortality steadily increased as the delay in antibiotic administration increased (one hour: . %, . % to . %; > hours:
. %, . % to . %).
period followed by a six month period of restricted use of high chloride uids (normal saline, % albumin) suggested that high chloride uids may cause acute kidney injury (odds ratio for AKI during restricted period . , . to . ). Although a recent double blind RCT of ICU patients in New Zealand reported no reduction in AKI with bu ered crystalloid compared with saline ( g ), the population was low to moderate risk for this outcome and exposure to the study uid was modest (mean about L).
Resuscitation volume
It is widely considered standard of care to administer several liters of uid in severe sepsis and septic shock (as was the case in all patients in the three recent large trials). No high quality RCT evidence exists to support this practice, and a single randomized study of critically ill children large multicenter randomized controlled trials (RCTs) from the US (ProCESS ), the UK (ProMISe ), and Australia and Asia (ARISE ) have been published (> patients in total) that each compared the EGDT protocol with usual care ( g ). These three studies all found that EGDT did not signi cantly a ect survival, indicating that other improvements in sepsis and critical care explain the improved outcomes. Uncertainties still exist regarding the optimal type of uid, the optimal volume, and the best way to monitor the response to therapy.
Fluid type
Level I evidence suggests that starches should be avoided, and that albumin is not clearly bene cial relative to crystalloid ( g ).
A prospective open label pilot study of ICU patients during a control The recent TRISS study that randomized nearly patients with septic shock in Scandinavian ICUs to a transfusion threshold of or g/L hemoglobin found no di erence in day mortality or the rate of ischemic events ( g ).
Other supportive care Improvements in general critical care have played a major role in improving outcomes in sepsis.
Lung protective ventilation
In , low tidal volume ventilation in patients with ARDS was shown to have a marked survival bene t, with an absolute reduction in hospital mortality of . %. A subsequent analysis showed that this bene t extended to patients with sepsis who had ARDS. The adoption of low tidal volume, lung protective ventilation in patients with sepsis and ARDS has been a major factor in the improvement in outcomes over the past years.
Restrictive fluid therapy once initial resuscitation is accomplished
In a trial of patients with ARDS randomized to a conservative or liberal uid management strategy (once out of shock), the conservatively managed patients had a better oxygenation index and higher number of ventilator-free days ( . ( . ) v . ( . ); P< .
). Notably, there were trends towards improved survival ( . % v . %, P= . ) and less dialysis within days in the conservatively managed patients ( % v %; P= . ).
Use of sedatives
With the recognition that the excessive use of sedatives is probably harmful, -many hospitals have now implemented protocols to reduce unnecessary sedation. Awake patients are more capable of rehabilitation, and the early mobilization of critically ill patients improves delirium and functional outcomes as well as reducing the duration of mechanical ventilation.
Catheters and tubes
Rates of ventilator associated pneumonia have decreased, partly because of the engineering of endotracheal tubes to decrease bio lm formation and microaspiration, as well as improved oral hygiene. Improvements in intravascular catheter design, placement technique, maintenance, and timely removal have reduced nosocomial infections, as have criteria for the removal of unnecessary urinary catheters.
Nutrition and glucose management
Despite these advances, several questions remain regarding the optimal supportive care of patients with sepsis. The proper timing and intensity of nutritional support remains unclear. There is some weak older evidence for reduced infectious complications with enteral feeding, but recent randomized trials report no bene t with more aggressive enteral or parenteral nutritional supplementation.
These results have led the SSC to recommend enteral feedings as tolerated. Patients with sepsis are o en hyperglycemic, yet the optimal glucose target is in resource poor settings lacking advanced therapies for pulmonary edema questioned its safety. Nonetheless, it remains expert opinion that the decrease in septic shock mortality over the past several decades re ects in part the bene ts of early uid resuscitation.
Resuscitation adequacy
Over the past several decades many ICU physicians have moved away from the assessment of static cardiac lling pressures and towards dynamic indices of physiology. These include ultrasound assessments of central venous volume and le ventricular function, although it is worth reiterating that the evidence basis for trying to augment cardiac output in patients with sepsis is weak. Furthermore, excessive uid administration in the setting of a more permeable endothelium can exacerbate organ dysfunction, including the development of acute respiratory failure from ARDS. In addition, multiple investigators have shown that positive uid balance in these patients is an independent risk factor for death.
Lactate clearance was popularized by a study in patients with sepsis that showed non-inferiority to EGDT, and although not used in the recent three large negative trials of EGDT, many practitioners continue to measure serial lactate values to inform resuscitation targets. The optimal systemic blood pressure is also unknown, with a recent study reporting that targeting a mean arterial pressure of -mm Hg compared with -mm Hg modestly improved renal function, although rates of atrial brillation were increased and no di erence in survival was seen ( g ).
Timing and choice of vasopressors
It is unclear when vasopressors should be started during the resuscitation of septic shock. Most practitioners give at least -L crystalloid or colloid to adults before starting a vasopressor. Although some advocate giving more uid in an attempt to avoid the use of vasopressors, it is worth noting that vasopressors also constrict the large venous capacitance vessels and thus augment cardiac preload in addition to a erload.
Although limited by its retrospective design and reliance on complex statistical methods, a recent evaluation of the interaction between uid and vasopressor administration in nearly patients with septic shock found that mortality was lowest when vasopressors were started one to six hours a er onset and when at least L of uid was given during the rst hour.
A systematic review of randomized trials of patients with shock found no convincing evidence for the superiority of one vasopressor over another. However, an in uential meta-analysis from reported a higher mortality associated with dopamine than with norepinephrine (noradrenaline). Accordingly, the most recent SSC guidelines recommend norepinephrine as rst line agent, epinephrine (adrenaline) or low dose vasopressin as second line agents, and the avoidance of dopamine and phenylephrine as empiric vasopressor therapy.
Transfusion threshold
ProCESS, ProMISe, and ARISE suggested that a strategy of increasing oxygen delivery with red blood cell transfu-Heterogeneity also derives from biological variability related to the patient's:
• • The pathogen that is causing the sepsis.
Imagine a trial of a novel therapeutic approach to treating con rmed Gram negative septic shock for patients admitted within six hours, a seemingly narrow slice of sepsis. It is likely that large baseline di erences in innumerable biological processes would obscure a modest or even strong therapeutic signal for survival if the following patients were compared in the study:
• A year old female athlete who became ill two hours earlier with meningococcal sepsis
• An year old man with dementia and longstanding urinary retention, E coli bacteremia, and aspiration pneumonia complicated by ARDS
• A year old man with diverticulitis and an associated abscess but no bacteremia. Strategies to reduce heterogeneity include limiting enrollment on the basis of the above list of criteria or using biomarkers to help enrich for the targeted underlying pathophysiology. These approaches could be aided by more thorough analyses of failed phase III trials (although data are o en still held by the drug companies ) to identify subgroups of patients who appeared to derive bene t. Although these kinds of strategies have been used (for example, IL-levels to stratify patients in an anti-TNF trial, g ) and are probably necessary, they increase the costs of research and reduce the generalizability of the results.
Multiple pathways to injury
In a remarkable study in which low dose intravenous endotoxin was given to volunteers (a seemingly modest stimulus), thousands of genes in leukocytes were found to undergo large temporally dynamic changes, and more recent work has shown similar complexity in the changes of small molecule metabolites. As outlined in detail above, the molecular cascades and organ dysfunction that o en accompany sepsis are parallel and o en self reinforcing. Thus, even when patient heterogeneity is reduced and pathophysiology is conserved, it may be naive to expect that blocking one among hundreds of pathways will be su cient to produce a measurable clinical improvement. Furthermore, gains from blocking one pathway may be more than o set by unintended consequences. For example, reducing neutrophil recruitment and activation may attenuate injury from in ammation at the expense of reduced bacterial killing and wider dissemination of infection.
Possible solutions include identifying and targeting the key proximal regulatory pathways that orchestrate subsequent responses, or alternatively (given the obviunknown. Notably, targeting a glucose ofmg/dL ( mg/dL= . mmol/L), compared with < mg/dL, in a mixed population of critically ill patients has been shown to increase day mortality (odds ratio . , . to . ), and the SSC now recommends insulin therapy to maintain glucose < mg/dL.
Additional uncertainties
Other uncertainties include the optimal sedative regimen and the timing and dose of renal replacement therapy, -with current guidelines recommending either continuous or intermittent dialysis to help manage uid balance in patients with septic shock.
Molecular targeted sepsis therapies
The seminal preclinical TNF-α experiments from the s (see above) generated enthusiasm for the hypothesis that blocking proin ammatory cytokine cascades in sepsis would reduce mortality. However, a subsequent clinical trial in patients with septic shock showed that treatment with anti-TNF antibodies increased mortality. Similarly, corticosteroids were reported as early as to reduce mortality in septic shock dramatically, yet a er dozens of subsequent trials, there is still no consensus about e cacy. This pattern of promising preclinical and early clinical results followed by disappointing large phase III and IV trials has been repeated dozens of times in the past four decades for drugs targeting a variety of cytokine pathways, bacterial virulence factors, and the coagulation cascade ( g ).
Reasons for failure and possible remedies Much has been written about the reasons that most targeted molecular therapies have been unsuccessful in patients, and a few key points are worth emphasizing here. Beyond the standard challenges of optimizing pharmacokinetics and length of treatment, sepsis research has been confronted by other serious di culties.
Patient heterogeneity
Some researchers have argued that the de nition of sepsis using broad clinical criteria results in so much heterogeneity that therapies e ective for a "generic" patient with sepsis may be impossible to nd. Others have argued that severe sepsis and septic shock may represent distinct disease phenotypes that occur independently rather than on a continuum. But even when clinical criteria are narrowed, challenges remain. Recruiting patients into clinical trials is arduous and time intensive. Although TNF was shown in preclinical models to rise and fall quickly at the beginning of sepsis, the clinical trial with etanercept (that demonstrated harm) enrolled patients at varying times a er the onset of sepsis. Even when patients are recruited within a narrow window a er admission their presentation may have been delayed, so the true onset of infection is o en unknowable. Temporal heterogeneity is a formidable obstacle in trials of anti-in ammatory agents in sepsis because patients tend to progress from a state of in ammatory cytokines into a state of immunosuppression: agents that might be helpful early in a patient's course could be harmful later. One promising approach is the use of cell based therapies such as allogeneic mesenchymal stem or stromal cells, which have potent immunomodulatory, antimicrobial, bioenergetic, and barrier enhancing e ects. These cells are currently being tested in phase II trials for ARDS and in a Canadian phase I trial in sepsis (NCT ). As the science evolves, we are likely to develop novel therapeutic strategies that optimize the host's response to infection. Simultaneously we must redouble e orts worldwide at more e ectively deploying proven infection prevention measures, including access to safe drinking water and sanitation, public health system surveillance and outreach, vector control, and vaccination.
Guidelines and the new sepsis definitions
The SSC was formed in as a collaboration of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. The SSC published its rst guidelines in . These guidelines made graded recommendations regarding diagnostics, antibiotics, uid and vasopressor resuscitation, mechanical ventilation, sedation, and the use of drotrecogin alfa (activated protein C; g ). Critics noted that the SSC derived % of its initial funding from Eli Lilly (maker of drotrecogin alfa), and that established therapies such as antibiotics and uids received lower ratings (owing to lack of RCT evidence) than did drotrecogin alfa. In , the SSC began publishing highly in uential quality indicators (sepsis bundles) based on their guidelines, which included many components of the EGDT approach, including measurement of central venous oxygen saturation in septic shock. The SSC has since divested itself of industry support and has periodically updated its guidelines, most recently in . A er the publication of ProCESS, ARISE, and ProMISe, the SSC released a brief update to its guidelines in April of ( http://www.survivingsepsis.org/SiteCollectionDocuments/SSC_Bundle.pdf ), which puts less emphasis than EGDT does on achieving speci c hemodynamic goals.
In February , a new consensus de nition and clinical criteria for sepsis were issued by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. Building on previous iterations of consensus de nitions, the new Sepsis-de nitions eliminate the SIRS category and put more emphasis on scoring organ dysfunction. Additionally, a new clinical sepsis screening tool was proposed to identify patients with sepsis outside of the ICU. Developed using logistic regression on established datasets and termed quick SOFA, this score still awaits prospective validation in diverse clinical settings. The screen is positive if two out of the following are true-respiratory rate > , Glasgow coma score < , systolic blood pressure < mm Hg. Notably, the syndromes of sepsis and septic shock as newly de ned in Sepsis-remain broad categorizations that do not separate patients on the basis of pathophysiologic mechanisms. Whether this revised set of diagnostic criteria will improve clinical trial design or the clinical care of patients remains to be determined. ous practical challenges of delivering therapeutics early enough to accomplish this) intervening in multiple downstream pathways simultaneously. Thus, trials involving combinations of therapies may be needed. Also, point of care testing that would allow better phenotyping of the patient's clinical and biological pro le could select patients more optimally for trials of new therapeutics, an approach that was recently evaluated in patients with ARDS.
Limitations of preclinical models
The most commonly used murine models of sepsis include endotoxin administration, cecal ligation and puncture, and exogenously administered pathogenic bacteria. Almost without exception inbred, young healthy animals are studied, and typically no advanced monitoring is used and minimal or no supportive care is given (antibiotics, respiratory support including supplemental oxygen, uid and vasopressor resuscitation, renal replacement therapy). Beyond these obvious differences from the composition and care of patients with sepsis, important species di erences probably explain many of the discrepancies between preclinical successes and clinical trial failures in drug development. For example, mice are notoriously resistant to endotoxin (a sterile and thus arti cial insult), requiring orders of magnitude higher doses than are needed in humans to cause illness.
An influential study published in compared the response of transcriptional networks of circulating mouse and human leukocytes to burns, endotoxin, and trauma. A er nding little correlation between human and murine responses, the authors argued provocatively that translational research should shi away from mouse models. However, several important limitations of this study were highlighted in a recent review that makes a strong case for enhancing the relevance of murine models (rather than abandoning them) by including the use of outbred strains of di erent ages and shi ing away from endotoxin models towards bacterial infections of the lungs, urinary tract, and abdomen. Other appealing approaches include the use of larger animal models (such as sheep) with the inclusion of at least some forms of supportive care, recognizing that most patients no longer die of the acute in ammatory response but of subsequent organ failure.
Emerging treatments
Several large phase III and IV clinical trials are currently under way ( g ). In light of the substantial improvements in sepsis outcomes with advances in supportive critical care, the current trials seek to further optimize uid, hemodynamic, and sedative management. A er many failures of strategies seeking to decrease the in ammatory cascades in early sepsis, the focus of immunomodulatory research has shi ed to attempts to boost immunity during the later phase of immunoparalysis.
Recognizing that multiple organ failure is responsible for much of the clinical burden of sepsis, early stage research has increasingly focused on strategies to enhance endothelial and epithelial barrier function, 
Conclusions
The study of the impact, pathogenesis, and treatment of sepsis has generated important new insights at every level of analysis. Sepsis remains a common, expensive, and deadly problem throughout the world. It is a complicated and dynamic condition that resists one size ts all approaches. However, despite the failure of many therapeutics in clinical trials, sepsis outcomes have improved substantially with major improvements in supportive care, including rapid recognition of sepsis and delivery of e ective antibiotics, resuscitation with uid therapy in early septic shock, lung protective ventilation, more judicious use of uid therapy once shock has resolved, better guidelines for blood product transfusion, and enhanced methods to reduce secondary nosocomial infections. Novel therapeutic pathways targeting organ dysfunction hold renewed promise for both septic and sterile in ammation, but thoughtful preclinical approaches will be essential going forward. In addition, to reduce heterogeneity and enhance the prospects of therapeutic e cacy for new treatment strategies, the use of clinical and biological criteria to select and phenotype patients with sepsis for clinical trials will need to be improved.
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